文献速递白血病造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

儿童急性淋巴细胞白血病CAR-T细胞治疗后继发性血液学发育异常

Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children.
PubMed 文献 · Br J Haematol · 2024-10-28

在西班牙巴塞罗那圣若望德德乌医院接受CAR-T治疗的106例急性淋巴细胞白血病患儿中,40例无早期复发或后续治疗,其中4例符合WHO骨髓发育异常标准。4例均在接受CAR-T前已行造血干细胞移植,CAR-T后出现血细胞减少伴骨髓严重发育异常;1例为宿主来源的高危细胞遗传学克隆性MDS需行造血干细胞移植,3例为供者来源的非进展性发育异常。这是儿童CAR-T后MDS和血液学发育异常的首例描述,强调需监测CAR-T后持续性血细胞减少的患儿。

要点

  • 106例接受CAR-T的ALL患儿中,40例无早期复发或后续治疗者中4例符合WHO骨髓发育异常标准。
  • 4例均有CAR-T前造血干细胞移植史,CAR-T后出现血细胞减少伴骨髓严重发育异常。
  • 1例为宿主来源的高危细胞遗传学克隆性MDS需行造血干细胞移植,3例为供者来源非进展性发育异常。

核心结论

  • 这是儿童CAR-T后MDS和血液学发育异常的首例描述,强调需监测CAR-T后持续性血细胞减少的患儿。

研究设计与样本

  • 研究纳入西班牙巴塞罗那圣若望德德乌医院接受CAR-T细胞治疗的所有儿童,对持续性血细胞减少者进行细胞学、细胞遗传学和分子学评估以寻找MDS。
  • 共106例患儿因急性淋巴细胞白血病接受CAR-T治疗。

主要发现

  • 106例接受CAR-T的ALL患儿中,40例无早期复发或CAR-T后后续治疗。
  • 40例中4例符合WHO骨髓发育异常标准,这4例均在CAR-T前接受过造血干细胞移植,CAR-T后出现血细胞减少伴骨髓严重发育异常。
  • 1例为宿主细胞来源的克隆性MDS伴高危细胞遗传学,需行造血干细胞移植。
  • 3例为供者细胞来源的非进展性发育异常;其中2例存活并处于完全缓解、血细胞减少稳定,1例死于ALL复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of CAR-T is becoming more widespread in the treatment of haematological malignancies. In adults, secondary myelodysplastic syndromes (MDS) after CAR-T have been described. However, there are currently no data on the risk of MDS following CAR-T in children treated for acute lymphoblastic leukaemia (ALL). We studied all children treated with CAR-T cells at Hospital Sant Joan de Déu in Barcelona and those with persistent cytopenias were evaluated at the cytological, cytogenetic, and molecular levels to look for MDS. A total of 106 patients received CAR-T for ALL. Among 40 patients without early relapse or subsequent therapy after CAR-T, four fulfilled the WHO criteria for myelodysplasia. These four patients had received a haematopoietic stem cell transplantation (HSCT) prior to CAR-T and presented cytopenias with severe dysplastic changes in bone marrow after CAR-T. One patient had clonal MDS with high-risk cytogenetics arising from the host cells requiring a HSCT. Three patients had non-progressive dysplasia arising from the donor cells. Two are alive in complete remission with stable cytopenias and one succumbed to ALL relapse. This is the first description of post-CAR-T MDS and haematological dysplasia in children and highlights the need to monitor children with persistent post-CAR-T cytopenias.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Theron A, Alonso-Saladrigues A, Dapena JL, et al. Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children. Br J Haematol. 2024. PMID: 39463072. doi:10.1111/bjh.19862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。